June 12, 2023

WEST CHESTER Pa — Papyrus Therapeutics Inc., a biotechnology platform company for the development of potent, multi-cancer, tumor suppressor precision therapies for solid cancers, is pleased to announce Daniel Soland’s appointment as Chief Operating Officer. Dan is an experienced biopharmaceutical executive who combines innovation with exceptional leadership skills to grow successful biopharmaceutical companies and achieve bottom line results. His key areas of expertise include strategic and commercial planning and execution, manufacturing, and quality systems across organizations, all with an international perspective.

Dr. Paul Blake FRCP, CEO of Papyrus Therapeutics said “We are excited by the appointment of Dan as our Chief Operating Officer. He has a tremendous track record for building sustainable development and commercial operations for small and large biopharmaceutical companies in the US and internationally that were based on small molecule and protein-based therapeutics. His experience and expertise are a strong complement to the current management team. Dan will greatly enhance Papyrus’ success as a leader in OPCML tumor suppression therapeutics as we progress into the clinic and commercially with our lead drug, PYTX-004.”

Dan currently sits on the boards of Acadia Pharmaceuticals in the US and of DBV Technologies in France. He formerly served on the boards of Kalvista in the US and Oxford Biomedica in the UK, the latter position until he was appointed CEO of UniQure BV in the Netherlands.

Previously, Dan served as Chief Operating Officer for Idera Pharmaceuticals until its merger with Aceragen, Chief Operating Officer for Viropharma until its purchase by Shire plc, and President of Chiron Vaccines until its purchase by Novartis. Prior to that he was President and CEO of Epigenesis following his role as VP and Director of Worldwide Marketing operations for GSK Biologicals based in Philadelphia and in Belgium. Before these appointments, he was VP of the US vaccine business of SmithKline Beecham and before that he held several positions at Connaught Laboratories following his first position in the pharmaceutical industry as a sales representative for Eli Lilly after qualifying in Pharmacy from the University of Iowa.

About Papyrus Therapeutics Inc.:

Papyrus Therapeutics, Inc. (West Chester, PA, USA) is a biotherapeutics platform company developing novel tumor suppressor-based therapies. Papyrus´ lead therapeutic is a modified, recombinant analogue of Opioid Binding Protein/Cell Adhesion Molecule-like (r-OPCML-Fc), PYTX-004. PYTX-004 is a native engineered OPCML protein replacement therapy designed to suppress tumor growth. Unlike chemotherapy, PYTX-004 targets only cancer cells without damaging healthy cells and is anticipated to be a well-tolerated treatment.

OPCML is a broadly acting tumor suppressor that is epigenetically silenced in many cancers, leading to tumor invasion and metastasis through deregulation of apoptosis, epithelial-to-mesenchymal transition (EMT) and cellular migration. Classic receptor tyrosine kinase [RTK] inhibition using small molecules has proven highly effective in many cancers, but treatment resistance remains a significant challenge. Delivery of OPCML, which works at the cell surface, can overcome this challenge by reconstituting normal RTK signaling in the tumor.


Dr. Paul Blake